HANSOH PHARMA (03692) announced its annual results for the period ended December 31, 2025. The group recorded revenue of RMB 150.28 billion, representing a year-on-year increase of 22.57%. Profit attributable to owners of the parent company was RMB 55.55 billion, a rise of 27.07% compared to the previous year. Basic earnings per share were RMB 0.93. The board proposed a final dividend of HK 20.0 cents per share.
The company is a leading innovation-driven pharmaceutical enterprise in China, with a mission to "continuously innovate and improve the quality of human life." It focuses on major therapeutic areas including anti-tumor, anti-infective, central nervous system (CNS), metabolic, and autoimmune diseases. The company currently has seven innovative drugs generating sales revenue in China, forming a robust product pipeline.
For the year ended December 31, 2025, sales revenue from innovative drugs and collaboration products amounted to approximately RMB 123.54 billion, accounting for about 82.2% of total revenue. This has become the core driver for the group's sustainable performance growth. The company's revenue is primarily derived from the sale of pharmaceutical products, which are concentrated in its strategically focused key therapeutic areas, including anti-tumor, anti-infective, central nervous system, metabolic, and other diseases. The increases in revenue, annual profit, and basic earnings per share during the reporting period were mainly attributable to the growth in sales revenue from innovative drugs and collaboration products.
Comments